Sleep Apnea and Cardiovascular Risk: CPAP Evidence and Alternatives

Mandibular Advancement Devices and Hypoglossal Nerve Stimulation

Custom-fitted mandibular advancement devices (MADs) reduce AHI by approximately 50% and are recommended for mild-to-moderate OSA or for patients with moderate-to-severe OSA who are CPAP-intolerant. The SARAH trial demonstrated that MADs are non-inferior to CPAP for blood pressure reduction in hypertensive OSA patients[8], likely because higher adherence compensates for lower per-hour efficacy. Hypoglossal nerve stimulation (Inspire, implantable neurostimulator) is indicated for moderate-to-severe OSA (AHI 15-65) with CPAP failure and BMI below 40, after drug-induced sleep endoscopy confirms absence of complete concentric palatal collapse. The STAR trial demonstrated AHI reduction from 29 to 9 events/hour at 12 months, sustained through 5-year follow-up[5].

Weight Management and Emerging Pharmacotherapy

Weight loss remains the most effective non-PAP intervention for OSA. A 10% weight loss reduces AHI by approximately 26-50%. The SURMOUNT-OSA trial demonstrated that tirzepatide reduced AHI by 51-53% in patients with moderate-to-severe OSA and obesity[6], a magnitude comparable to CPAP therapy, raising the possibility of pharmacotherapy as a primary OSA treatment in obese patients. GLP-1 receptor agonists may emerge as an important adjunctive or even first-line approach for OSA management in the obese population.

Honest Conversations About CPAP and Cardiovascular Protection

The most common question patients ask about CPAP is whether it will protect them from heart attacks and strokes. The honest answer, based on the current evidence, is: probably, but only if you use it consistently for at least four hours per night, and the definitive trial proving this has not been conducted. What CPAP reliably does is improve daytime sleepiness, cognitive function, quality of life, and blood pressure — benefits that are meaningful on their own terms regardless of the cardiovascular endpoint data. Framing the CPAP discussion around these established, patient-centered outcomes rather than the more uncertain cardiovascular benefit helps set realistic expectations and may paradoxically improve adherence, because patients who wear CPAP for how it makes them feel today are more likely to sustain use than patients wearing it to prevent a heart attack in twenty years.

Limitations and the Adherence Paradox

The fundamental limitation of the OSA-cardiovascular evidence base is the adherence paradox: the trials that were large enough to detect cardiovascular outcomes had low average CPAP adherence, while the observational data showing cardiovascular benefit come from patients who were adherent — a self-selected population likely different in multiple ways from non-adherent patients. Whether the cardiovascular benefit is truly caused by CPAP or confounded by the characteristics of people who use CPAP consistently cannot be definitively resolved by the current evidence. The emergence of weight-loss pharmacotherapy as an OSA treatment may eventually sidestep this issue entirely by providing a treatment modality with inherently better adherence — a daily or weekly injection rather than a nightly mask — though the long-term cardiovascular effects of this approach in OSA are not yet established.

References

1. Sleep disordered breathing and mortality: eighteen-year follow-up of the Wisconsin sleep cohort
2. CPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea
3. CPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea
4. CPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea
5. Upper-airway stimulation for obstructive sleep apnea
6. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA)
7. Telemonitoring and CPAP adherence: TeleOSA randomized trial
8. Mandibular advancement device versus CPAP for blood pressure reduction in OSA